0001493152-22-023943.txt : 20220824 0001493152-22-023943.hdr.sgml : 20220824 20220824155323 ACCESSION NUMBER: 0001493152-22-023943 CONFORMED SUBMISSION TYPE: DFAN14A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20220824 DATE AS OF CHANGE: 20220824 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: Pasithea Therapeutics Corp. CENTRAL INDEX KEY: 0001841330 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 851591963 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DFAN14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-40804 FILM NUMBER: 221191476 BUSINESS ADDRESS: STREET 1: 2110 NARCISSUS CT CITY: VENICE STATE: CA ZIP: 90291 BUSINESS PHONE: 8184226172 MAIL ADDRESS: STREET 1: 2110 NARCISSUS CT CITY: VENICE STATE: CA ZIP: 90291 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: Camac Fund, LP CENTRAL INDEX KEY: 0001516478 IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DFAN14A BUSINESS ADDRESS: STREET 1: CAMAC CAPITAL, LLC STREET 2: 350 PARK AVENUE, 13TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: 914-629-8496 MAIL ADDRESS: STREET 1: CAMAC CAPITAL, LLC STREET 2: 350 PARK AVENUE, 13TH FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 DFAN14A 1 formdfan14a.htm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

SCHEDULE 14A

(Rule 14A-101)

 

PROXY STATEMENT PURSUANT TO SECTION 14(a)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Filed by the Registrant ☐

Filed by a Party other than the Registrant ☒

 

Check the appropriate box:

 

☐ Preliminary Proxy Statement
☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
☐ Definitive Proxy Statement
☒ Definitive Additional Materials
☐ Soliciting Material under § 240.14a-12

 

Pasithea Therapeutics Corp.

(Name of Registrant as Specified in its Charter)

 

Concord IP2 Ltd.

Elderhill Corporation

Leonite Capital LLC

Leonite Fund I, LP

Camac Partners, LLC

Camac Capital, LLC

Camac Fund, LP

David Delaney

Avi Geller

Eric Shahinian

(Name of Person(s) Filing Proxy Statement, if other than the Registrant)

 

Payment of Filing Fee (Check all boxes that apply):

 

☒No fee required
☐Fee paid previously with preliminary materials
☐Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

 

 

 

 

 

 

Investor Group Urges Stockholders of Pasithea Therapeutics to Vote to Call Special Meeting

 

—Near Threshold Required, Every Vote Matters—

 

NEW YORK AND TORONTO — BUSINESS WIRE — Camac Partners, LLC, affiliates of Concord Investment Partners Ltd., and Leonite Capital LLC (collectively with their affiliates, the “Investor Group” or “we”), who together are one of the largest stockholders of Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), today issued the following letter to their fellow stockholders:

 

August 24, 2022

 

Dear Pasithea Stockholders,

 

As you know, we are seeking to call a Special Meeting of Stockholders at Pasithea for a simple reason: we have lost all confidence in the incumbent Board of Directors to be effective and prudent stewards of our capital. Each of us are substantial investors in Pasithea, and we don’t want to see that investment squandered by directors who are more interested in taking care of themselves and their hand-picked allies than stockholders.

 

We have been pleased with the high degree of investor engagement and support we have received thus far, such that we are close to the threshold needed to call the special meeting. But EVERY VOTE COUNTS. If you have not returned your proxy card in support of our efforts, please do so immediately, either by reaching us directly or through InvestorCom, whose contact information is below. Thank you!

 

Contacts

For Investors:

InvestorCom LLC

John Grau, 203-972-9300

info@investor-com.com